Insmed is trading 11.34% higher at $107.97 after third-quarter revenue of $524.4 million topped analyst expectations.
- BRINSUPRI sales were $400.1 million; Insmed raised its 2026 revenue outlook for BRINSUPRI and ARIKAYCE.
- The rally came despite a wider-than-expected quarterly loss and weaker broader markets. Shares closed at $96.98 on October 28.
- Live volume was not provided.